Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BREAKING: Bitcoin is ABOVE $108K - New All-Time High Just Days Away?

BREAKING: Bitcoin is ABOVE $108K - New All-Time High Just Days Away?

CryptotickerCryptoticker2025/06/29 23:56
By:Cryptoticker

Bitcoin Price Analysis: Chart Breakout Signals Massive Upside Potential

Bitcoin ($BTC) is showing renewed strength after breaking the critical $108,000 resistance — a level that had previously capped multiple rallies in June. This fresh bullish momentum comes just after a powerful macro tailwind: U.S. President Donald Trump stated in a speech that “Bitcoin takes pressure off the dollar.” The market interpreted this as a green light for crypto’s long-term legitimacy — and traders are reacting accordingly.

BTC Coin Technical Setup: Bullish Breakout Confirmed?

On the 4H chart, BTC has finally pushed out of the descending triangle structure (orange lines), confirming a bullish breakout. The breakout candle is clean and supported by volume, suggesting continuation. The next key level to watch is $109,000 — the horizontal resistance that now stands as the final wall before Bitcoin can test its all-time high of $112,000.

  • EMA 200 (blue line): Price is now trading comfortably above the 200 EMA at ~$105,138, reinforcing the shift in trend direction.
  • RSI (14): Currently sits at 64.70, approaching the overbought zone — but not yet in reversal territory. This implies room for upside, though a cooldown might occur before the next leg.
  • Support Zones: In case of a pullback, strong support lies at $105,000 and then $103,343. If BTC dips into that range, it could offer a high-probability re-entry point.

BTC/USD 4-hours chart - TradingView

Entry and Exit Strategy: What Traders Should Watch

Entry Ideas:

  • Break and Retest Strategy: Wait for BTC to retest the breakout zone around $108,000. A successful retest and bounce could offer a strong long entry toward the ATH.
  • Aggressive Entry: Enter now with tight stop-loss below $106,500, aiming for the next breakout at $109,000 and then ATH levels.

Targets:

  • $109,000 – First major resistance.
  • $112,000 – All-Time High.
  • $115,000+ – If BTC breaks the ATH, the next psychological magnet is around $115K–$118K.

Stop-Loss Suggestion:

Below $105,000, where the 200 EMA and prior structure support reside. A break below that could invalidate the current bullish thesis.

Trump Bitcoin Statement Sparks Institutional Confidence

Donald Trump’s unexpected endorsement of Bitcoin as a pressure relief valve for the U.S. dollar has given BTC bulls a much-needed catalyst. 

Combined with:

  • Upcoming $40B BTC options expiry
  • Ongoing institutional inflows
  • ETF performance tailwinds

…it’s no surprise the market is gaining steam heading into Q3 2025.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf

Crossing the break-even line, the growth inflection point has arrived.

智通财经•2026/11/11 03:22

Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot

Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.

智通财经•2026/11/11 03:06

Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality

The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

智通财经•2026/11/11 02:56
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality